Pandemic influenza A(H1N1pdm09) vaccine induced high levels of influenza-specific IgG and IgM antibodies as analyzed by enzyme immunoassay and dual-mode multiplex microarray immunoassay methods

Vaccine ◽  
2020 ◽  
Vol 38 (8) ◽  
pp. 1933-1942 ◽  
Author(s):  
Anna Kazakova ◽  
Laura Kakkola ◽  
Thedi Ziegler ◽  
Ritva Syrjänen ◽  
Henna Päkkilä ◽  
...  
1970 ◽  
Vol 25 (2) ◽  
pp. 82-87 ◽  
Author(s):  
MR Norzuriza ◽  
W Kon Ken ◽  
M Mohammad ◽  
I Isahak ◽  
MM Rahman

An epidemiological investigation was carried out on patients reported to Hospital University Kebangsaan Malaysia (HUKM) suspected to be carriers of Epstein-Barr virus from July 2005 to June 2006. A total of 402 patients' sera were analyzed by Enzyme Immunoassay with Kit Enzygnost® by automated BEP® 2000 instrument. Of these 91.3% were found to carry Epstein-Barr virus (EBV) antibodies. Among these, 90.4%of male and 92.2% of female patients were positive: the difference was not significant. Considering community, 91.9% of Malay, 91.9% of Chinese, 75% of Indian and 93.3% of others were positive: the differences were not significant. Among the age groups, 77.5% of 0-20 year-olds, 98.6% of 21-40 year-olds, 96% of 41-60 year-olds and 100% of those above 60 years of age were positive: these differences were significant (p<0.005). No significant difference in the prevalence of EBV antibodies existed between the months of sampling. In the present study, EBV-specific IgG and IgM antibodies were determined. The proportion of samples positive to IgM was much less than those positive to IgG. DOI: 10.3329/bvet.v25i2.4622 Bangl. vet. 2008. Vol. 25, No. 2, 82-87


Author(s):  
José Alberto Choreño-Parra ◽  
Luis Armando Jiménez-Álvarez ◽  
Gustavo Ramírez-Martínez ◽  
Alfredo Cruz-Lagunas ◽  
Mahima Thapa ◽  
...  

Abstract The differentiation of influenza and COVID-19 could constitute a diagnostic challenge during the ongoing winter due to their clinical similitude. Thus, novel biomarkers that enable distinguishing both diseases are required. Here, we evaluated whether the surfactant protein D (SP-D), a collectin produced at the alveolar epithelium with known immune properties, was useful to differentiate pandemic influenza A(H1N1) from COVID-19 in critically ill patients. Our results revealed high serum SP-D levels in severe pandemic influenza but not COVID-19 patients. This finding was validated in a separate cohort of mechanically ventilated COVID-19 patients who also showed low plasma SP-D levels. However, plasma SP-D levels did not distinguish seasonal influenza from COVID-19 in mild-to-moderate disease. Finally, we found that high serum SP-D levels were associated with mortality and renal failure among severe pandemic influenza cases. Thus, our studies have identified SP-D as a unique biomarker expressed during severe pandemic influenza but not COVID-19.


npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Marion Borey ◽  
Fany Blanc ◽  
Gaëtan Lemonnier ◽  
Jean-Jacques Leplat ◽  
Deborah Jardet ◽  
...  

AbstractThis study describes the associations between fecal microbiota and vaccine response variability in pigs, using 98 piglets vaccinated against the influenza A virus at 28 days of age (D28) with a booster at D49. Immune response to the vaccine is measured at D49, D56, D63, and D146 by serum levels of IAV-specific IgG and assays of hemagglutination inhibition (HAI). Analysis of the pre-vaccination microbiota characterized by 16S rRNA gene sequencing of fecal DNA reveals a higher vaccine response in piglets with a richer microbiota, and shows that 23 operational taxonomic units (OTUs) are differentially abundant between high and low IAV-specific IgG producers at D63. A stronger immune response is linked with OTUs assigned to the genus Prevotella and family Muribaculaceae, and a weaker response is linked with OTUs assigned to the genera Helicobacter and Escherichia-Shigella. A set of 81 OTUs accurately predicts IAV-specific IgG and HAI titer levels at all time points, highlighting early and late associations between pre-vaccination fecal microbiota composition and immune response to the vaccine.


Viruses ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 516
Author(s):  
Shuyi Yang ◽  
Keith R. Jerome ◽  
Alexander L. Greninger ◽  
Joshua T. Schiffer ◽  
Ashish Goyal

While SARS-CoV-2 specific neutralizing antibodies have been developed for therapeutic purposes, the specific viral triggers that drive the generation of SARS-CoV-2 specific IgG and IgM antibodies remain only partially characterized. Moreover, it is unknown whether endogenously derived antibodies drive viral clearance that might result in mitigation of clinical severity during natural infection. We developed a series of non-linear mathematical models to investigate whether SARS-CoV-2 viral and antibody kinetics are coupled or governed by separate processes. Patients with severe disease had a higher production rate of IgG but not IgM antibodies. Maximal levels of both isotypes were governed by their production rate rather than different saturation levels between people. Our results suggest that an exponential surge in IgG levels occurs approximately 5–10 days after symptom onset with no requirement for continual antigenic stimulation. SARS-CoV-2 specific IgG antibodies appear to have limited to no effect on viral dynamics but may enhance viral clearance late during primary infection resulting from the binding effect of antibody to virus, rather than neutralization. In conclusion, SARS-CoV-2 specific IgG antibodies may play only a limited role in clearing infection from the nasal passages despite providing long-term immunity against infection following vaccination or prior infection.


2010 ◽  
Vol 16 (S2) ◽  
pp. 1122-1123
Author(s):  
CS Goldsmith ◽  
MG Metcalfe ◽  
W-J Shieh ◽  
DM Blau ◽  
DC Rollin ◽  
...  

Extended abstract of a paper presented at Microscopy and Microanalysis 2010 in Portland, Oregon, USA, August 1 – August 5, 2010.


Sign in / Sign up

Export Citation Format

Share Document